Aimed Bio Valuation Multiples
Aimed Bio is valued at $866M as of November 2026, a 22.8x revenue multiple. In the last fiscal year, Aimed Bio revenue was $35M and Aimed Bio EBITDA was ($3M).
Aimed Bio Overview
About Aimed Bio
Aimed Bio Inc is a preclinical-stage biotechnology company specializing in the development of antibody-based therapeutics, especially antibody-drug conjugates (ADC) and bispecific antibodies. It is a next-generation anticancer technology designed to maximize therapeutic efficacy and reduce side effects compared to existing chemotherapeutic agents by selectively delivering anticancer drugs to cancer cells via antibodies. Its product pipelines are AMB302, AMB303, AMB001, and Others.
Founded
2018
HQ
Employees
51
Website
Financials (Last FY)
EV
$798M
Valuation Multiples
Start free trial
Aimed Bio Financials
Aimed Bio reported last fiscal year revenue of $35M and negative EBITDA of ($3M).
In the same fiscal year, Aimed Bio generated $35M in gross profit, ($3M) in EBITDA losses, and $4M in net income.
Aimed Bio P&L
In the most recent fiscal year, Aimed Bio reported revenue of $35M and EBITDA of ($3M).
Aimed Bio is profitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (10%), and net margin of 11%.
Financial data powered by Morningstar, Inc.
Aimed Bio Stock Performance
Aimed Bio has current market cap of $866M, and enterprise value of $798M.
Market Cap Evolution
Aimed Bio's stock price is $13.49.
Aimed Bio share price decreased by 4.4% in the last 30 days.
Aimed Bio has an EPS (earnings per share) of $0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $798M | $866M | -0.1% | -4.4% | -24.3% | - | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAimed Bio Valuation Multiples
Aimed Bio trades at 22.8x EV/Revenue multiple, and (236.5x) EV/EBITDA.
Aimed Bio Financial Valuation Multiples
As of November 8, 2026, Aimed Bio has market cap of $866M and EV of $798M.
Aimed Bio has a P/E ratio of 233.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aimed Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aimed Bio Margins & Growth Rates
In the most recent fiscal year, Aimed Bio reported gross margin of 100%, EBITDA margin of (10%), and net margin of 11%.
Aimed Bio Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
Aimed Bio Operational KPIs
Aimed Bio's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Aimed Bio Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Aimed Bio competitors and their valuation data. Start Free Trial | ||||||
Aimed Bio VC Funding History
Before going public, Aimed Bio raised $66M in total equity funding, across 2 rounds.
Aimed Bio Funding Rounds
Investments by Aimed Bio
Aimed Bio has invested in 1 company to date.
Latest investment by Aimed Bio was on June 30th 2026. Aimed Bio invested in Inocras in their Strategic investment round.
Latest Investments by Aimed Bio
| Description | Inocras is a San Francisco-headquartered genomics firm offering AI-analyzed whole genome sequencing. Its CAP/CLIA lab processes CancerVision for tumor profiling, RareVision for Mendelian disorders, and MRDVision for infectious agents. Inocras serves pharma partners like Genentech with proprietary pipelines on AWS, enabling clinical trials since 2021. |
| HQ Country |  |
| HQ City | San Diego, CA |
| Deal Date | 30 Jun 2026 |
| Round | Strategic investment |
| Raised | undisclosed |
| Investors | Aimed Bio |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Aimed Bio investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aimed Bio
| When was Aimed Bio founded? | Aimed Bio was founded in 2018. |
| Where is Aimed Bio headquartered? | Aimed Bio is headquartered in South Korea. |
| How many employees does Aimed Bio have? | As of today, Aimed Bio has over 51 employees. |
| Is Aimed Bio publicly listed? | Yes, Aimed Bio is a public company listed on Korea Exchange. |
| What is the stock symbol of Aimed Bio? | Aimed Bio trades under 0009K0 ticker. |
| When did Aimed Bio go public? | Aimed Bio went public in 2025. |
| Who are competitors of Aimed Bio? | Aimed Bio main competitors include |
| What is the current market cap of Aimed Bio? | Aimed Bio's current market cap is $866M. |
| What is the current revenue of Aimed Bio? | Aimed Bio's last fiscal year revenue is $35M. |
| What is the current EV/Revenue multiple of Aimed Bio? | Current revenue multiple of Aimed Bio is 22.8x. |
| Is Aimed Bio profitable? | No, Aimed Bio is not profitable. |
| How many companies Aimed Bio has acquired to date? | Aimed Bio hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Aimed Bio has invested to date? | As of November 2026, Aimed Bio has invested in 1 company. |
| What was the last Aimed Bio investment? | On 30th June 2026 Aimed Bio invested in Inocras, participating in a Strategic investment round. |
| In what companies Aimed Bio invested in? | Aimed Bio invested in Inocras. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.